AstraZeneca reported 11% revenue growth, excluding a 1% currency headwind, and 14% core operating profit growth with full-year guidance of high single-digit revenue growth and low-double-digit core earnings per share growth. Enhertu (oncology) sales grew 42% in the quarter, with strong uptake in China and the US. China sales also grew 5% despite headwinds from generics. The fair value estimate for AstraZeneca is maintained at GBX 12,400 per ordinary share and $81 for the US ADR. Management anticipates no long-term impact from hypothetical tariffs on drugs. Key events over the next 12 months include Avanzar for Datroway, baxdrostat’s phase 3 data presentation, and early breast cancer trials for Enhertu.

Read more at Morningstar: AstraZeneca Q2 Earnings: Full-Year Guidance Unchanged